{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:49:49Z","timestamp":1781056189062,"version":"3.54.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI24\/00215"],"award-info":[{"award-number":["PI24\/00215"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RYC2021\\u2013031346-I"],"award-info":[{"award-number":["RYC2021\\u2013031346-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CNS2024\\u2013154299"],"award-info":[{"award-number":["CNS2024\\u2013154299"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["963845"],"award-info":[{"award-number":["963845"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118459","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T16:24:20Z","timestamp":1755275060000},"page":"118459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Unravelling drug-induced hepatic steatosis: Clinical sub-phenotypes, outcome prediction, and identification of high-concern drugs and hazardous chemical attributes"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6684-8731","authenticated-orcid":false,"given":"Marta","family":"Moreno-Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-8365","authenticated-orcid":false,"given":"Ernesto","family":"L\u00f3pez-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-4736","authenticated-orcid":false,"given":"Anna","family":"Rapisarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Lindeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1275-9498","authenticated-orcid":false,"given":"Anouk","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Luechtefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Serrano-Candelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Dirven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vinken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 V.","family":"Castell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Jover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118459_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.118459_bib2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bj\u00f6rnsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118459_bib3","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/ajg.2012.138","article-title":"A prospective nationwide study of drug-induced liver injury in korea","volume":"107","author":"Suk","year":"2012","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"10.1016\/j.biopha.2025.118459_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/hepr.13288","article-title":"Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan","volume":"49","author":"Aiso","year":"2019","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.biopha.2025.118459_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bj\u00f6rnsson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.118459_bib6","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/ajg.2010.287","article-title":"Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality","volume":"105","author":"Devarbhavi","year":"2010","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"10.1016\/j.biopha.2025.118459_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1872-034X.2008.00486.x","article-title":"Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006","volume":"39","author":"Takikawa","year":"2009","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.biopha.2025.118459_bib8","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of Drug-Induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118459_bib9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118459_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-Induced liver injury: an analysis of 461 incidences submitted to the spanish registry over a 10-Year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118459_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2021.01.029","article-title":"Comprehensive analysis and insights gained from long-term experience of the spanish Dili registry","volume":"75","author":"Stephens","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118459_bib12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/1751-2980.12612","article-title":"Chronic liver injury induced by drugs and toxins","volume":"19","author":"Ortega-Alonso","year":"2018","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.biopha.2025.118459_bib13","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in Drug-Induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118459_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118459_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.26709","article-title":"Hepatic histological findings in suspected Drug-Induced liver injury: systematic evaluation and clinical associations","volume":"59","author":"Kleiner","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.118459_bib16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/ijms17050714","article-title":"Case characterization, clinical features and risk factors in drug-Induced liver injury","volume":"17","author":"Ortega-Alonso","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118459_bib17","first-page":"1299","article-title":"Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients","volume":"7","author":"Murata","year":"2000","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2025.118459_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1478-3231.1999.tb00053.x","article-title":"Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers","volume":"19","author":"Cotrim","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.biopha.2025.118459_bib19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.46.2.465","article-title":"Valproic acid hepatic fatalities. Iii. U.S. experience since 1986","volume":"46","author":"Bryant","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2025.118459_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/gut.25.6.673","article-title":"Hepatotoxicity to sodium valproate: a review","volume":"25","author":"Powell-Jackson","year":"1984","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.118459_bib21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.20074","article-title":"Valproate therapy and nonalcoholic fatty liver disease","volume":"55","author":"Luef","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2025.118459_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.37349\/edd.2023.00034","article-title":"Deciphering the liver enigma: distinguishing Drug-Induced liver injury and metabolic dysfunction-associated steatotic liver disease\u2014a comprehensive narrative review","volume":"2","author":"Garc\u00eda-Cort\u00e9s","year":"2023","journal-title":"Explor. Dig. Dis."},{"key":"10.1016\/j.biopha.2025.118459_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116530","article-title":"Novel clinical phenotypes, drug categorization, and outcome prediction in Drug-Induced cholestasis: analysis of a database of 432 patients developed by literature review and machine learning support","volume":"174","author":"Moreno-Torres","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2025.118459_bib24","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.2174\/138920012802850001","article-title":"Drug-Induced liver steatosis and phospholipidosis: Cell-Based assays for early screening of drug candidates","volume":"13","author":"Donato","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.biopha.2025.118459_bib25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/biomedicines10010194","article-title":"Detailed molecular mechanisms involved in drug-induced non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: an update","volume":"10","author":"Di Pasqua","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118459_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/frai.2021.685298","article-title":"Sysrev: a FAIR platform for data curation and systematic evidence review","volume":"4","author":"Bozada","year":"2021","journal-title":"Front. Artif. Intell."},{"key":"10.1016\/j.biopha.2025.118459_bib27","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to Drugs\u2014II. an original model for validation of drug causality assessment methods: case reports with positive rechallenge","volume":"46","author":"Benichou","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.biopha.2025.118459_bib28","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to Drugs--I. a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.biopha.2025.118459_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00730","article-title":"Idiosyncratic Dili: analysis of 46,266 cases assessed for causality by RUCAM and published from 2014 to early 2019","volume":"10","author":"Teschke","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118459_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pr."},{"key":"10.1016\/j.biopha.2025.118459_bib31","doi-asserted-by":"crossref","unstructured":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet Lond. Engl. 2021, 398, 957\u2013980, doi:10.1016\/S0140-6736(21)01330-1.","DOI":"10.1016\/S0140-6736(21)01330-1"},{"key":"10.1016\/j.biopha.2025.118459_bib32","unstructured":"More than One Billion People Now Living with Obesity, Global Analysis Suggests | Imperial News | Imperial College London Available online: \u3008https:\/\/www.imperial.ac.uk\/news\/251798\/more-than-billion-people-living-with\/\u3009 (accessed on 8 May 2025)."},{"key":"10.1016\/j.biopha.2025.118459_bib33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3350\/cmh.2020.0160","article-title":"Global and regional impacts of alcohol use on public health: emphasis on alcohol policies","volume":"26","author":"Park","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118459_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101499","article-title":"Alcohol-related liver disease: a global perspective","volume":"29","author":"Narro","year":"2024","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.biopha.2025.118459_bib35","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jhep.2016.05.003","article-title":"Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury","volume":"65","author":"Medina-Caliz","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118459_bib36","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-Induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118459_bib37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.5604\/16652681.1171749","article-title":"Drug-induced fatty liver disease: an overview of pathogenesis and management","volume":"14","author":"Satapathy","year":"2015","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.biopha.2025.118459_bib38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0041-008X(89)90252-4","article-title":"Investigation into the mechanism of tetracycline-Induced steatosis: study in isolated hepatocytes","volume":"97","author":"Deboyser","year":"1989","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118459_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00442614","article-title":"The effect of L-Asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia","volume":"147","author":"Cremer","year":"1988","journal-title":"Eur. J. Pediatr."},{"issue":"156","key":"10.1016\/j.biopha.2025.118459_bib40","first-page":"39","article-title":"From the cover: potentiation of Drug-Induced phospholipidosis in vitro through PEGlyated graphene oxide as the nanocarrier","author":"Yang","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.biopha.2025.118459_bib41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fphar.2018.00257","article-title":"Effect of toxicants on fatty acid metabolism in HepG2 cells","volume":"9","author":"Gr\u00fcnig","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118459_bib42","unstructured":"Methotrexate. In LiverTox: clinical and research information on drug-induced liver injury; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD), 2012."},{"key":"10.1016\/j.biopha.2025.118459_bib43","doi-asserted-by":"crossref","unstructured":"Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program. Diabetes 2005, 54, 1150\u20131156.","DOI":"10.2337\/diabetes.54.4.1150"},{"key":"10.1016\/j.biopha.2025.118459_bib44","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1086\/383151","article-title":"Nucleoside analogues and mitochondrial toxicity","volume":"38","author":"Fleischer","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118459_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.biopha.2025.118459_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101205","article-title":"Vinyl chloride-induced interaction of nonalcoholic and toxicant-associated steatohepatitis: protection by the ALDH2 activator Alda-1","volume":"24","author":"Chen","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2025.118459_bib47","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/archinte.1989.00390080065015","article-title":"Van thiel, D.H. Liver disease associated with exposure to 1,1,1 -Trichloroethane","volume":"149","author":"Hodgson","year":"1989","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.biopha.2025.118459_bib48","unstructured":"Ketoconazole. In LiverTox: clinical and research information on drug-induced liver injury; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD), 2012."},{"key":"10.1016\/j.biopha.2025.118459_bib49","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/00042737-200108000-00018","article-title":"Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria","volume":"13","author":"Grieco","year":"2001","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118459_bib50","unstructured":"Acute Fatty Liver with Lactic Acidosis and Hepatic Dysfunction. In LiverTox: clinical and research information on drug-induced liver injury; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD), 2012."},{"key":"10.1016\/j.biopha.2025.118459_bib51","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.3390\/ijms25105203","article-title":"Drug-Induced fatty liver disease (DIFLD): a comprehensive analysis of clinical, biochemical, and histopathological data for mechanisms identification and consistency with current adverse outcome pathways","volume":"25","author":"L\u00f3pez-Pascual","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118459_bib52","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118459_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/apha.14150","article-title":"Unlocking mitochondrial drug targets: the importance of mitochondrial transport proteins","volume":"240","author":"Hoogstraten","year":"2024","journal-title":"Acta Physiol."},{"key":"10.1016\/j.biopha.2025.118459_bib54","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1042\/bj1051283","article-title":"Biliary excretion in foreign compounds. Sulphonamide drugs in the rat","volume":"105","author":"Millburn","year":"1967","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2025.118459_bib55","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1042\/bj1051275","article-title":"Biliary excretion of foreign compounds. Biphenyl, stilboestrol and phenolphthalein in the rat: molecular weight, polarity and metabolism as factors in biliary excretion","volume":"105","author":"Millburn","year":"1967","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2025.118459_bib56","unstructured":"Unlocking mitochondrial drug targets: the importance of mitochondrial transport proteins - Hoogstraten - 2024 - Acta Physiologica - Wiley Online Library Available online: \u3008https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/apha.14150\u3009 (accessed on 6 May 2025)."},{"key":"10.1016\/j.biopha.2025.118459_bib57","doi-asserted-by":"crossref","unstructured":"Pore, S.; Roy, K. Insights into pharmacokinetic properties for exposure chemicals: predictive modelling of human plasma fraction unbound ( f u) and Hepatocyte Intrinsic Clearance (Cl Int) Data Using Machine Learning. 2024, doi:10.1039\/D4DD00082J.","DOI":"10.1039\/D4DD00082J"},{"key":"10.1016\/j.biopha.2025.118459_bib58","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/phar.1965","article-title":"Clinical importance of monitoring unbound valproic acid concentration in patients with hypoalbuminemia","volume":"37","author":"Dor\u00e9","year":"2017","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.biopha.2025.118459_bib59","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1007\/s11095-015-1749-4","article-title":"Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS)","volume":"32","author":"Varma","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2025.118459_bib60","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.28678","article-title":"A model to predict severity of drug-induced liver injury in humans","volume":"64","author":"Chen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.118459_bib61","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.118459_bib62","doi-asserted-by":"crossref","first-page":"17031","DOI":"10.18632\/oncotarget.4400","article-title":"A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications","volume":"6","author":"Weng","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118459_bib63","series-title":"Handbook of Computational Chemistry","article-title":"Predicting ADME properties of chemicals","author":"Shin","year":"2017"},{"key":"10.1016\/j.biopha.2025.118459_bib64","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1063\/1.1579474","article-title":"Predicting aqueous solubilities from aqueous free energies of solvation and experimental or calculated vapor pressures of pure substances","volume":"119","author":"Thompson","year":"2003","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.biopha.2025.118459_bib65","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00894-005-0065-z","article-title":"Computational approaches for modeling human intestinal absorption and permeability","volume":"12","author":"Subramanian","year":"2006","journal-title":"J. Mol. Model"},{"key":"10.1016\/j.biopha.2025.118459_bib66","first-page":"802","article-title":"Structure, function and regulation of P-Glycoprotein and its clinical relevance in drug disposition","volume":"38","author":"Sf","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.biopha.2025.118459_bib67","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy\u2019s law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.biopha.2025.118459_bib68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with Drug-Induced liver injury","volume":"147","author":"Robles-Diaz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118459_bib69","first-page":"2360","article-title":"Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy\u2019s law and a new prognostic model","volume":"13","author":"Lo Re","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.biopha.2025.118459_bib70","unstructured":"N, C.; C, K.; F, F.; A, P.; A, M.; Ej, B.; P, P.; S, S.; J, S. Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding."},{"key":"10.1016\/j.biopha.2025.118459_bib71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cld.2017.08.004","article-title":"Diagnosis and evaluation of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis, including noninvasive biomarkers and transient elastography","volume":"22","author":"Tsai","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.biopha.2025.118459_bib72","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","article-title":"DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans","volume":"21","author":"Chen","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2025.118459_bib73","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/diagnostics15131588","article-title":"Drug-induced autoimmune hepatitis: robust causality assessment using two different validated and scoring diagnostic algorithms","volume":"15","author":"Teschke","year":"2025","journal-title":"Diagnostics"},{"key":"10.1016\/j.biopha.2025.118459_bib74","first-page":"1116","article-title":"Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study","volume":"46","author":"Licata","year":"2014","journal-title":"Liver Pancreas Biliary Trac."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:15:23Z","timestamp":1772810123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225006535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":74,"alternative-id":["S0753332225006535"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118459","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unravelling drug-induced hepatic steatosis: Clinical sub-phenotypes, outcome prediction, and identification of high-concern drugs and hazardous chemical attributes","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118459"}}